XML 201 R89.htm IDEA: XBRL DOCUMENT v3.25.1
SEGMENT REPORTING (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Revenue $ 13,712,528 $ 14,584,473 $ 54,426,402 $ 53,376,874
Cost of Sales (11,662,729) (13,250,847) (50,115,079) (49,027,305)
GROSS PROFIT 2,049,799 1,333,626 4,311,323 4,349,569
General and administrative expenses (1,478,702) (1,418,138) (11,733,237) (19,642,005)
Salaries (1,040,019) (1,258,179) (5,693,436) (4,554,909)
Sales and marketing expenses (28,155) (173,630) (354,969) (1,204,636)
Research and development costs     (533,293)  
General and administrative expenses     (7,038,805)  
Segment profit / (loss)     (9,915,045)  
Depreciation and amortization (320,439) (319,787) (1,249,238) (614,377)
Share-based Compensation Expense 556,611 340,194 1,689,712 577,931
Foreign currency transaction, net 175,824 (161,254) (121,530) 198,863
Net finance costs     (605,865)  
Other income and expenses     (32,323)  
Net profit/(loss) before Income Taxes (818,097) (1,866,690) (16,183,018) (18,542,654)
Provision     (4,694,432)  
Impairment Charges     (291,980) 0
Research and development costs     533,293  
Cost of Sales 11,662,729 13,250,847 50,115,079 49,027,305
Sales and marketing expenses 28,155 $ 173,630 354,969 $ 1,204,636
Other [Member]        
Revenue 0   0  
Cost of Sales 0   0  
GROSS PROFIT 0      
General and administrative expenses (361,140)   (4,176,049)  
Salaries (255)   (1,317,580)  
Sales and marketing expenses 0   (88,405)  
Research and development costs (15,629)   (533,293)  
Segment profit / (loss) (377,024)   (6,115,592)  
Depreciation and amortization (35,778)   (118,448)  
Share-based Compensation Expense (556,613)      
Foreign currency transaction, net 6,454      
Net finance costs     (265)  
Other income and expenses (193,593)   40,718  
Net profit/(loss) before Income Taxes (1,156,555)   (6,324,354)  
Provision     0  
Impairment Charges     (131,032)  
Research and development costs 15,629   533,293  
Cost of Sales 0   0  
Sales and marketing expenses 0   88,405  
Total Segment [Member]        
Revenue 13,712,528      
Cost of Sales (11,662,729)      
GROSS PROFIT 2,049,799      
General and administrative expenses (922,090)      
Salaries (1,040,019)      
Sales and marketing expenses (28,155)      
Research and development costs (15,629)      
Net finance costs (95,781)      
Segment profit / (loss) (51,875)      
Depreciation and amortization (320,439)      
Share-based Compensation Expense (556,613)      
Foreign currency transaction, net 175,825      
Other income and expenses (64,995)      
Net profit/(loss) before Income Taxes (818,097)      
Research and development costs 15,629      
Cost of Sales 11,662,729      
Sales and marketing expenses 28,155      
Wholesale [Member]        
Revenue 12,504,562   51,593,787  
Cost of Sales (11,320,936)   (48,887,569)  
GROSS PROFIT 1,183,626      
General and administrative expenses (162,269)   (647,225)  
Salaries (378,595)   (1,701,552)  
Sales and marketing expenses (715)   (10,516)  
Research and development costs 0   0  
Segment profit / (loss) 492,773   (493,531)  
Depreciation and amortization (52,880)   (231,344)  
Share-based Compensation Expense 0      
Foreign currency transaction, net 59,428      
Net finance costs     (840,456)  
Other income and expenses 27,556   (304,495)  
Net profit/(loss) before Income Taxes 526,877   (2,051,188)  
Provision     (1,021,818)  
Impairment Charges     0  
Research and development costs 0   0  
Cost of Sales 11,320,936   48,887,569  
Sales and marketing expenses 715   10,516  
Pharma manufacturing [Member]        
Revenue 268,557   865,373  
Cost of Sales (70,975)   (249,061)  
GROSS PROFIT 197,582      
General and administrative expenses (155,454)   (773,429)  
Salaries (363,670)   (1,243,568)  
Sales and marketing expenses (428)   (489)  
Research and development costs 0   0  
Segment profit / (loss) (321,970)   (1,401,174)  
Depreciation and amortization (131,974)   (565,371)  
Share-based Compensation Expense 0      
Foreign currency transaction, net 0      
Net finance costs     0  
Other income and expenses 12,341   5,789  
Net profit/(loss) before Income Taxes (441,603)   (2,084,259)  
Provision     (123,503)  
Impairment Charges     0  
Research and development costs 0   0  
Cost of Sales 70,975   249,061  
Sales and marketing expenses 428   489  
Nutraceuticals and Pharmaceuticals [Member]        
Revenue 939,409   1,967,242  
Cost of Sales (270,818)   (978,449)  
GROSS PROFIT 668,591      
General and administrative expenses (243,227)   (1,442,102)  
Salaries (297,499)   (1,430,736)  
Sales and marketing expenses (27,012)   (255,559)  
Research and development costs 0   0  
Segment profit / (loss) 154,346   (1,904,748)  
Depreciation and amortization (99,807)   (334,075)  
Share-based Compensation Expense 0      
Foreign currency transaction, net 109,943      
Net finance costs     (234,856)  
Other income and expenses 88,701   225,665  
Net profit/(loss) before Income Taxes 253,184   (5,723,217)  
Provision     (3,549,111)  
Impairment Charges     (160,948)  
Research and development costs 0   0  
Cost of Sales 270,818   978,449  
Sales and marketing expenses $ 27,012   $ 255,559